Cardio Connections Summit: Lipids, Lp(a) and Valve Disease

Explore the latest advancements in cardiovascular care for nurses by diving into critical updates in lipid management, early and targeted strategies, and recognizing the hidden risks of Lipoprotein(a). Discover how to enhance aortic stenosis care with cutting-edge AI tools, early TAVR interventions, and strategies to overcome care barriers, especially for women. Join us to earn 1.5 CE and gain practical insights to elevate your practice.

Agenda

Learning Objectives

Rethinking Lipids: Early, Aggressive, and Targeted Strategies in the New Dyslipidemia Guidelines

• Summarize the key updates in the newly released lipid management guidelines.
• Explain the rationale for earlier treatment of dyslipidemia to reduce atherosclerotic exposure, including thresholds for initiating therapy and the importance of timely screening using tools such as lipid panels, PREVENT risk calculator, and coronary artery calcium (CAC) scoring.
• Differentiate between primary and secondary prevention strategies in dyslipidemia management, including appropriate use of statins, non-statin therapies (e.g., ezetimibe, PCSK9 inhibitors, inclisiran), lifestyle interventions, and monitoring practices for diverse patient populations.

Aortic Stenosis: Enhancing Care with AI, Early TAVR, and Breaking Barriers

• Compare traditional treatment with updated diagnostic criteria and risk stratification tools that support early transcatheter aortic valve replacement (TAVR) in asymptomatic patients, including interpretation of echocardiographic and biomarker findings.
• Examine the structural and systemic barriers contributing to delayed diagnosis and reduced access to TAVR in women, and apply strategies to advocate for equitable care.
• Evaluate the use of emerging digital technologies—such as AI-assisted echocardiography interpretation, remote patient monitoring, shared decision-making tools, and predictive analytics—to support earlier detection, risk assessment, and post-TAVR care coordination in patients with aortic stenosis.

Thank you to Merck & Co., Inc., Novartis Pharmaceuticals, and the Family Heart Foundation for their support of this program.

Accreditation